- Illumina (NASDAQ:ILMN) introduces its new next-generation sequencing (NGS) system, the NextSeq 550Dx which it says covers a broad range of clinical applications of interest to almost any clinical laboratory.
- It also announces that has updated its MiSeq Dx instrument to include the use of DNA libraries generated from formalin-fixed paraffin-embedded (FFPE) tissues which enables clinical labs to use FFPE samples when developing new test applications.
Illumina launches new automated NGS system NextSeq 550Dx
Recommended For You
More Trending News
About ILMN Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
ILMN | - | - |
Illumina, Inc. |